Profile
Sector:
HealthcareIndustry:
BiotechnologyCountry:
United StatesIPO:
17 February 2021Website:
http://www.virpaxpharma.comNext earnings report:
06 December 2024Last dividends:
N/ANext dividends:
N/APrice
after hours | Fri, 01 Nov 2024 23:04:18 GMTDividend
Analysts recommendations
Institutional Ownership
VRPX Latest News
Virpax Pharmaceuticals (NASDAQ: VRPX ) stock is rocketing higher on Wednesday after the preclinical-stage pharmaceutical company announced positive results from a swine model pilot study. Virpax Pharmaceuticals has released results from its swine model study of Probudur.
Wednesday, Virpax Pharmaceuticals Inc VRPX released results for a Swine Model pilot study for Probudur, Virpax's long-acting liposomal bupivacaine formulation injected at a wound site to provide immediate and extended pain relief.
Virpax Pharmaceuticals (NASDAQ: VRPX ) stock is heading higher on Monday after the preclinical-stage pharmaceutical company secured a new $2.5 million loan. Virpax Pharmaceuticals says that this funding comes from an institutional investor.
What type of business is Virpax Pharmaceuticals?
Virpax Pharmaceuticals, Inc., a preclinical-stage pharmaceutical company, develops various drug-delivery systems and drug-releasing technologies focused on advancing non-opioid and non-addictive pain management treatments and treatments for central nervous system disorders. Its preclinical stage product candidates include Epoladerm, a topical spray film delivery technology for osteoarthritis pain; Probudur, an injectable local anesthetic liposomal gel technology for postoperative pain management; and Envelta, a nanotechnology-based intranasal spray drug product candidate that enables the delivery of a metabolically labile peptide drug into the brain. The company's preclinical stage product candidates also comprise AnQlar, an anti-viral barrier to prevent or reduce the risk or the intensity of viral infections in humans, including influenza and SARS-CoV-2; and NobrXiol, an investigational formulation to be delivered via the nasal route to enhance cannabidiol transport to the brain. Virpax Pharmaceuticals, Inc. was founded in 2016 and is headquartered in Berwyn, Pennsylvania.
What sector is Virpax Pharmaceuticals in?
Virpax Pharmaceuticals is in the Healthcare sector
What industry is Virpax Pharmaceuticals in?
Virpax Pharmaceuticals is in the Biotechnology industry
What country is Virpax Pharmaceuticals from?
Virpax Pharmaceuticals is headquartered in United States
When did Virpax Pharmaceuticals go public?
Virpax Pharmaceuticals initial public offering (IPO) was on 17 February 2021
What is Virpax Pharmaceuticals website?
https://www.virpaxpharma.com
Is Virpax Pharmaceuticals in the S&P 500?
No, Virpax Pharmaceuticals is not included in the S&P 500 index
Is Virpax Pharmaceuticals in the NASDAQ 100?
No, Virpax Pharmaceuticals is not included in the NASDAQ 100 index
Is Virpax Pharmaceuticals in the Dow Jones?
No, Virpax Pharmaceuticals is not included in the Dow Jones index
When was Virpax Pharmaceuticals the previous earnings report?
No data
When does Virpax Pharmaceuticals earnings report?
The next expected earnings date for Virpax Pharmaceuticals is 06 December 2024